Literature DB >> 25717210

Ferric citrate.

Dennis J Cada1, Jasen Cong2, Danial E Baker3.   

Abstract

Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation/medication use evaluation (DUE/MUE) is also provided each month. With a subscription, the monographs are sent in print and are also available on-line. Monographs can be customized to meet the needs of a facility. A drug class review is now published monthly with The Formulary Monograph Service. Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. For more information about The Formulary Monograph Service, call The Formulary at 800-322-4349. The February 2015 monograph topics are netupitant/palonosetron, naltrxone SR/bupropion SR, nintedanib, pirfenidone, and ivabradine. The Safety MUE is on netupitant/palonosetron.

Entities:  

Year:  2015        PMID： 25717210      PMCID： PMC4336017          DOI： 10.1310/hpj5002-139

Source DB:  PubMed          Journal:  Hosp Pharm        ISSN： 0018-5787


  18 in total

1.  K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease.

Authors: 
Journal:  Am J Kidney Dis       Date:  2003-10       Impact factor: 8.860

2.  A randomized trial of JTT-751 versus sevelamer hydrochloride in patients on hemodialysis.

Authors:  Keitaro Yokoyama; Takashi Akiba; Masafumi Fukagawa; Masaaki Nakayama; Kenichi Sawada; Yuji Kumagai; Glenn M Chertow; Hideki Hirakata
Journal:  Nephrol Dial Transplant       Date:  2013-12-26       Impact factor: 5.992

3.  Ferric citrate controls phosphorus and delivers iron in patients on dialysis.

Authors:  Julia B Lewis; Mohammed Sika; Mark J Koury; Peale Chuang; Gerald Schulman; Mark T Smith; Frederick C Whittier; Douglas R Linfert; Claude M Galphin; Balaji P Athreya; A Kaldun Kaldun Nossuli; Ingrid J Chang; Samuel S Blumenthal; John Manley; Steven Zeig; Kotagal S Kant; Juan Jose Olivero; Tom Greene; Jamie P Dwyer
Journal:  J Am Soc Nephrol       Date:  2014-07-24       Impact factor: 10.121

4.  Effect of oral JTT-751 (ferric citrate) on hyperphosphatemia in hemodialysis patients: results of a randomized, double-blind, placebo-controlled trial.

Authors:  Keitaro Yokoyama; Hideki Hirakata; Takashi Akiba; Kenichi Sawada; Yuji Kumagai
Journal:  Am J Nephrol       Date:  2012-11-07       Impact factor: 3.754

5.  Effect of oral ferric citrate on serum phosphorus in hemodialysis patients: multicenter, randomized, double-blind, placebo-controlled study.

Authors:  Chien-Te Lee; I-Wen Wu; Shou-Shan Chiang; Yu-Sen Peng; Kuo-Hsiung Shu; Ming-Ju Wu; Mai-Szu Wu
Journal:  J Nephrol       Date:  2014-05-20       Impact factor: 3.902

6.  Rationale and study design of a three-period, 58-week trial of ferric citrate as a phosphate binder in patients with ESRD on dialysis.

Authors:  Kausik Umanath; Mohammed Sika; Robert Niecestro; Carolyn Connelly; Gerald Schulman; Mark J Koury; Julia B Lewis; Jamie P Dwyer
Journal:  Hemodial Int       Date:  2012-06-15       Impact factor: 1.812

7.  New phosphate binding agents: ferric compounds.

Authors:  C H Hsu; S R Patel; E W Young
Journal:  J Am Soc Nephrol       Date:  1999-06       Impact factor: 10.121

8.  Ferric citrate hydrate, a new phosphate binder, prevents the complications of secondary hyperparathyroidism and vascular calcification.

Authors:  Akio Iida; Yusuke Kemmochi; Kochi Kakimoto; Minako Tanimoto; Takayuki Mimura; Yuichi Shinozaki; Atsuhiro Uemura; Akira Matsuo; Mutsuyoshi Matsushita; Ken-ichi Miyamoto
Journal:  Am J Nephrol       Date:  2013-03-23       Impact factor: 3.754

9.  An open-label, crossover study of a new phosphate-binding agent in haemodialysis patients: ferric citrate.

Authors:  Wu-Chang Yang; Chwei-Shiun Yang; Chun-Chen Hou; Tsai-Hung Wu; Eric W Young; Chen H Hsu
Journal:  Nephrol Dial Transplant       Date:  2002-02       Impact factor: 5.992

10.  The safety and tolerability of ferric citrate as a phosphate binder in dialysis patients.

Authors:  Marvin Sinsakul; Mohammed Sika; Mark Koury; Warren Shapiro; Tom Greene; Jamie Dwyer; Mark Smith; Stephen Korbet; Julia Lewis
Journal:  Nephron Clin Pract       Date:  2012-10-16
View more
  3 in total

1.  Safety and efficacy of ferric citrate in phosphate reduction and iron supplementation in patients with chronic kidney disease.

Authors:  Mei-Yi Wu; Ying-Chun Chen; Chun-Hung Lin; Yun-Chun Wu; Yu-Kang Tu; Der-Cherng Tarng
Journal:  Oncotarget       Date:  2017-10-20

2.  Effect of Phosphate Binders and a Dietary Iron Supplement on the Pharmacokinetics of a Single Dose of Vadadustat in Healthy Adults.

Authors:  Susan K Paulson; Jimena Martinez; Rishikesh Sawant; Steven K Burke; Ajit Chavan
Journal:  Clin Pharmacol Drug Dev       Date:  2022-02-16

3.  Iron-related parameters in dialysis patients treated with sucroferric oxyhydroxide.

Authors:  Adrian C Covic; Jürgen Floege; Markus Ketteler; Stuart M Sprague; Laura Lisk; Viatcheslav Rakov; Anjay Rastogi
Journal:  Nephrol Dial Transplant       Date:  2017-08-01       Impact factor: 5.992
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.